Thymoma and thymic carcinoma

Therapeutic approaches

Anupama Kurup, Patrick Loehrer

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Thymomas and thymic carcinomas, which are rare epithelial tumors arising from the thymus gland, are the most common tumors of the anterior mediastinum. Thymomas are generally encapsulated, slow-growing tumors that have a "bland" histologic appearance. Thymic carcinomas possess more overtly malignant histologic features than thymomas and are more likely to present as invasive or disseminated disease. Surgery is the treatment of choice for localized thymic tumors, with complete resection being the most important prognostic factor. Complete resection also improves survival in locally invasive thymic tumors. Adjuvant postoperative radiation therapy may improve the outcome in patients with invasive disease, although the data are conflicting. Multimodal regimens, including neoadjuvant combination chemotherapy, surgery, and/or postoperative radiation therapy, are recommended for patients with advanced thymomas and thymic carcinomas. Use of octreotide plus prednisone has produced responses in thymomas, but the dosing and schedule have not been clearly defined. Prospective studies have been limited, and, as such, enrollment in clinical trials is encouraged.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalClinical Lung Cancer
Volume6
Issue number1
StatePublished - Jul 2004

Fingerprint

Thymoma
Thymus Neoplasms
Therapeutics
Radiotherapy
Octreotide
Mediastinum
Prednisone
Combination Drug Therapy
Thymus Gland
Neoplasms
Appointments and Schedules
Clinical Trials
Prospective Studies
Survival

Keywords

  • Cisplatin
  • Cyclophosphamide
  • Doxorubicin
  • Etoposide
  • Ifosfamide
  • Masaoka staging
  • Octreotide
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Thymoma and thymic carcinoma : Therapeutic approaches. / Kurup, Anupama; Loehrer, Patrick.

In: Clinical Lung Cancer, Vol. 6, No. 1, 07.2004, p. 28-32.

Research output: Contribution to journalArticle

@article{6abd06850c734ec882c5f4a663253ff6,
title = "Thymoma and thymic carcinoma: Therapeutic approaches",
abstract = "Thymomas and thymic carcinomas, which are rare epithelial tumors arising from the thymus gland, are the most common tumors of the anterior mediastinum. Thymomas are generally encapsulated, slow-growing tumors that have a {"}bland{"} histologic appearance. Thymic carcinomas possess more overtly malignant histologic features than thymomas and are more likely to present as invasive or disseminated disease. Surgery is the treatment of choice for localized thymic tumors, with complete resection being the most important prognostic factor. Complete resection also improves survival in locally invasive thymic tumors. Adjuvant postoperative radiation therapy may improve the outcome in patients with invasive disease, although the data are conflicting. Multimodal regimens, including neoadjuvant combination chemotherapy, surgery, and/or postoperative radiation therapy, are recommended for patients with advanced thymomas and thymic carcinomas. Use of octreotide plus prednisone has produced responses in thymomas, but the dosing and schedule have not been clearly defined. Prospective studies have been limited, and, as such, enrollment in clinical trials is encouraged.",
keywords = "Cisplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Masaoka staging, Octreotide, Radiation therapy, Surgery",
author = "Anupama Kurup and Patrick Loehrer",
year = "2004",
month = "7",
language = "English",
volume = "6",
pages = "28--32",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Thymoma and thymic carcinoma

T2 - Therapeutic approaches

AU - Kurup, Anupama

AU - Loehrer, Patrick

PY - 2004/7

Y1 - 2004/7

N2 - Thymomas and thymic carcinomas, which are rare epithelial tumors arising from the thymus gland, are the most common tumors of the anterior mediastinum. Thymomas are generally encapsulated, slow-growing tumors that have a "bland" histologic appearance. Thymic carcinomas possess more overtly malignant histologic features than thymomas and are more likely to present as invasive or disseminated disease. Surgery is the treatment of choice for localized thymic tumors, with complete resection being the most important prognostic factor. Complete resection also improves survival in locally invasive thymic tumors. Adjuvant postoperative radiation therapy may improve the outcome in patients with invasive disease, although the data are conflicting. Multimodal regimens, including neoadjuvant combination chemotherapy, surgery, and/or postoperative radiation therapy, are recommended for patients with advanced thymomas and thymic carcinomas. Use of octreotide plus prednisone has produced responses in thymomas, but the dosing and schedule have not been clearly defined. Prospective studies have been limited, and, as such, enrollment in clinical trials is encouraged.

AB - Thymomas and thymic carcinomas, which are rare epithelial tumors arising from the thymus gland, are the most common tumors of the anterior mediastinum. Thymomas are generally encapsulated, slow-growing tumors that have a "bland" histologic appearance. Thymic carcinomas possess more overtly malignant histologic features than thymomas and are more likely to present as invasive or disseminated disease. Surgery is the treatment of choice for localized thymic tumors, with complete resection being the most important prognostic factor. Complete resection also improves survival in locally invasive thymic tumors. Adjuvant postoperative radiation therapy may improve the outcome in patients with invasive disease, although the data are conflicting. Multimodal regimens, including neoadjuvant combination chemotherapy, surgery, and/or postoperative radiation therapy, are recommended for patients with advanced thymomas and thymic carcinomas. Use of octreotide plus prednisone has produced responses in thymomas, but the dosing and schedule have not been clearly defined. Prospective studies have been limited, and, as such, enrollment in clinical trials is encouraged.

KW - Cisplatin

KW - Cyclophosphamide

KW - Doxorubicin

KW - Etoposide

KW - Ifosfamide

KW - Masaoka staging

KW - Octreotide

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=4444313479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444313479&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 28

EP - 32

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -